- Home
- DOMO vs TNGX Comparison
DOMO vs TNGX Comparison
Compare DOMO & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMO
- TNGX
- Stock Information
- Founded
- DOMO 2010
- TNGX 2014
- Country
- DOMO United States
- TNGX United States
- Employees
- DOMO N/A
- TNGX N/A
- Industry
- DOMO Computer Software: Prepackaged Software
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- DOMO Technology
- TNGX Health Care
- Exchange
- DOMO Nasdaq
- TNGX Nasdaq
- Market Cap
- DOMO 436.2M
- TNGX 351.2M
- IPO Year
- DOMO 2018
- TNGX N/A
- Fundamental
- Price
- DOMO $13.99
- TNGX $5.02
- Analyst Decision
- DOMO Hold
- TNGX Strong Buy
- Analyst Count
- DOMO 6
- TNGX 6
- Target Price
- DOMO $12.17
- TNGX $12.20
- AVG Volume (30 Days)
- DOMO 747.1K
- TNGX 4.0M
- Earning Date
- DOMO 05-21-2025
- TNGX 08-06-2025
- Dividend Yield
- DOMO N/A
- TNGX N/A
- EPS Growth
- DOMO N/A
- TNGX N/A
- EPS
- DOMO N/A
- TNGX N/A
- Revenue
- DOMO $317,052,000.00
- TNGX $40,990,000.00
- Revenue This Year
- DOMO $1.71
- TNGX N/A
- Revenue Next Year
- DOMO $2.43
- TNGX N/A
- P/E Ratio
- DOMO N/A
- TNGX N/A
- Revenue Growth
- DOMO N/A
- TNGX 10.09
- 52 Week Low
- DOMO $6.01
- TNGX $1.03
- 52 Week High
- DOMO $14.83
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- DOMO 62.60
- TNGX 69.44
- Support Level
- DOMO $11.97
- TNGX $4.70
- Resistance Level
- DOMO $13.75
- TNGX $5.63
- Average True Range (ATR)
- DOMO 0.74
- TNGX 0.60
- MACD
- DOMO -0.22
- TNGX -0.01
- Stochastic Oscillator
- DOMO 67.13
- TNGX 65.38
About DOMO Domo Inc. Class B
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.